Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Ann N Y Acad Sci ; 1054: 462-6, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16339698

RESUMO

The pervasiveness of low bone mass (LBM) in beta-thalassemia (Thal) patients (pts) is escalating as the average life expectancy of these pts increases. Adolescence is a period of substantial bone accrual, which is crucial for future bone strength. Studies of LBM are prevalent among adults with Thal. However, limited information exists about bone accrual and LBM in adolescents with the disease. Thirty-one pts with beta-Thal (26 Thal major [TM], 5 Thal intermedia [TI]), aged 9-20 years (mean: 15.3 years), 14 males and 17 females, underwent measurement of spinal bone mineral density (BMD) by DEXA (Lunar, Prodigy). Height, weight, body mass index, and Tanner stage were assessed at the time of the BMD measurement. A total of 16.1% of the patients had normal bone mass (Z > or = -1), 22.6% had reduced bone mass (Z = -1 to -2), and 61.3% had low bone mass (Z < or = -2). BMD Z correlated with height and weight Z scores. Some 53.9% of subjects had normal gonadal function and 46.1% had induced puberty with gonadal steroids. BMD Z significantly worsened with age (P < .0001). However, there was no difference in the LBM prevalence between subjects with normal versus those with induced puberty: BMD Z was -2 or less in 71.4% of subjects with normal puberty versus 66.7% in those with induced puberty. Our results indicate a high prevalence of LBM among adolescents with Thal regardless of adequate transfusion and chelation regimens. Bone accrual was found to be suboptimal in adolescents with normal or induced puberty. Thus, calcium and vitamin D supplementation with antiresorptive therapies should be evaluated in the adolescent Thal pt with close monitoring of growth and sexual development.


Assuntos
Densidade Óssea , Doenças Ósseas Metabólicas/etiologia , Osteoporose/etiologia , Talassemia beta/complicações , Adolescente , Adulto , Antropometria , Transfusão de Sangue , Doenças Ósseas Metabólicas/epidemiologia , Terapia por Quelação , Criança , Terapia Combinada , Desferroxamina/uso terapêutico , Progressão da Doença , Doenças do Sistema Endócrino/tratamento farmacológico , Doenças do Sistema Endócrino/epidemiologia , Doenças do Sistema Endócrino/etiologia , Feminino , Hormônios Esteroides Gonadais/uso terapêutico , Hormônio do Crescimento Humano/uso terapêutico , Humanos , Hipogonadismo/tratamento farmacológico , Hipogonadismo/epidemiologia , Hipogonadismo/etiologia , Quelantes de Ferro/uso terapêutico , Masculino , Osteoporose/epidemiologia , Prevalência , Puberdade Tardia/tratamento farmacológico , Puberdade Tardia/epidemiologia , Puberdade Tardia/etiologia , Coluna Vertebral/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA